Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

109.19 -1.34 (-1.21%)
Official Closing Price Updated: 7:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
News headline image
2 Reasons to Sell Merck Stock and 1 Reason to Buy ↗
Via The Motley Fool
News headline image
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025 ↗
The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip... 
Via Benzinga
News headline image
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market? ↗
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
News headline image
Uncovering Dividend Opportunities with NYSE:MRK. ↗
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill
News headline image
Is Merck the Next Big Weight-Loss Stock? ↗
Via The Motley Fool
News headline image
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Tumbled by More Than 10% This Week ↗
Via The Motley Fool
News headline image
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks ↗
Via The Motley Fool
News headline image
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump. ↗
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
News headline image
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? ↗
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Stocks That Could Turn $1,000 into $5,000 by 2030 ↗
Via The Motley Fool
News headline image
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials ↗
Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies. 
Via Benzinga
News headline image
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
News headline image
Stock Of The Day: Where Does The Merck Downtrend End? ↗
Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support and reverse. 
Via Benzinga
News headline image
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
News headline image
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
News headline image
What's Going On With Viking Therapeutics Stock On Wednesday? ↗
Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for future growth. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With Merck Shares Wednesday? ↗
Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese biopharmaceutical company Hansoh Pharma. 
Via Benzinga
News headline image
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
News headline image
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis ↗
Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA reviews RSV drug clesrovimab. 
Via Benzinga
News headline image
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? ↗
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
News headline image
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc. Merck
Via Business Wire
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients ↗
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.